We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Apellis Pharmaceuticals, Inc. (APLS - Free Report) reported $146.38 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 546%. EPS of -$0.73 for the same period compares to -$1.50 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $146.43 million, representing a surprise of -0.03%. The company delivered an EPS surprise of -10.61%, with the consensus EPS estimate being -$0.66.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Apellis Pharmaceuticals, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Product revenue, net: $138.66 million versus the eight-analyst average estimate of $138.12 million.
Licensing and other revenue: $7.72 million compared to the $8.30 million average estimate based on eight analysts.
Product Revenue- EMPAVELI: $24.39 million versus the two-analyst average estimate of $24.32 million.
Product Revenue - SYFOVRE: $114.27 million versus the two-analyst average estimate of $113.86 million.
Shares of Apellis Pharmaceuticals, Inc. have returned +9.8% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
Apellis Pharmaceuticals, Inc. (APLS - Free Report) reported $146.38 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 546%. EPS of -$0.73 for the same period compares to -$1.50 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $146.43 million, representing a surprise of -0.03%. The company delivered an EPS surprise of -10.61%, with the consensus EPS estimate being -$0.66.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Apellis Pharmaceuticals, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product revenue, net: $138.66 million versus the eight-analyst average estimate of $138.12 million.
- Licensing and other revenue: $7.72 million compared to the $8.30 million average estimate based on eight analysts.
- Product Revenue- EMPAVELI: $24.39 million versus the two-analyst average estimate of $24.32 million.
- Product Revenue - SYFOVRE: $114.27 million versus the two-analyst average estimate of $113.86 million.
View all Key Company Metrics for Apellis Pharmaceuticals, Inc. here>>>Shares of Apellis Pharmaceuticals, Inc. have returned +9.8% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.